Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
<p><strong>Background</strong> The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-...
Κύριοι συγγραφείς: | Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ |
---|---|
Άλλοι συγγραφείς: | Oxford COVID Vaccine Trial Group |
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Elsevier
2021
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
ανά: Emary, KRW, κ.ά.
Έκδοση: (2021) -
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
ανά: Marchevsky, NG, κ.ά.
Έκδοση: (2022) -
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
ανά: Voysey, M, κ.ά.
Έκδοση: (2023) -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
ανά: Clemens, SAC, κ.ά.
Έκδοση: (2021) -
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
ανά: Flaxman, A, κ.ά.
Έκδοση: (2021)